• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黏膜相关淋巴组织结外边缘区B细胞淋巴瘤组织学转化的风险及临床意义:一项基于人群的分析。

Risk and clinical implications of histological transformation in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: A population-based analysis.

作者信息

He Yujie, Gao Chengwen

机构信息

Medical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, Shangdong, 266000, China.

West Coast Second Hospital of Qingdao University Medical Group, Qingdao, Shangdong, 266000, China.

出版信息

Sci Rep. 2025 Jul 1;15(1):20407. doi: 10.1038/s41598-025-07413-8.

DOI:10.1038/s41598-025-07413-8
PMID:40596523
Abstract

Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) is the third most prevalent subtype of mature B-cell lymphomas. While MALT lymphoma typically has a favorable prognosis, the outlook can worsen dramatically if histological transformation (HT) occurs, usually into a more aggressive form like diffuse large B-cell lymphoma (DLBCL). Large-scale study with long-term follow-up specifically focused on the transformation of MALT lymphoma is limited. This study utilized the SEER database to analyze 20,944 patients diagnosed with MALT lymphoma from 2000 to 2020. We also included a cohort of de novo DLBCL patients for comparison. Our findings showed that HT occurred in 1.59% of MALT lymphoma cases, with 5- and 10-year cumulative incidences of 1.2% and 2.2%, respectively. Patients presenting with B symptoms, age ≥ 60, and advanced-stage disease were at a significantly higher risk for HT. The median time to transformation was 3.67 years. Both univariate and multivariate analyses demonstrated that age ≥ 60 was a significant adverse factor for lymphoma-specific survival (LSS) and overall survival (OS) following HT. This population-based study contributes to the characterization of transformation risk and outcomes in MALT lymphoma and may help inform clinical surveillance strategies.

摘要

黏膜相关淋巴组织(MALT)结外边缘区B细胞淋巴瘤是成熟B细胞淋巴瘤中第三常见的亚型。虽然MALT淋巴瘤通常预后良好,但如果发生组织学转化(HT),通常转化为更具侵袭性的形式,如弥漫性大B细胞淋巴瘤(DLBCL),预后可能会显著恶化。专门针对MALT淋巴瘤转化进行长期随访的大规模研究有限。本研究利用监测、流行病学和最终结果(SEER)数据库分析了2000年至2020年期间诊断为MALT淋巴瘤的20944例患者。我们还纳入了一组初发性DLBCL患者进行比较。我们的研究结果显示,1.59%的MALT淋巴瘤病例发生了HT,5年和10年累积发生率分别为1.2%和2.2%。出现B症状、年龄≥60岁和疾病晚期的患者发生HT的风险显著更高。转化的中位时间为3.67年。单因素和多因素分析均表明,年龄≥60岁是HT后淋巴瘤特异性生存(LSS)和总生存(OS)的显著不利因素。这项基于人群的研究有助于明确MALT淋巴瘤的转化风险和转归特征,并可能有助于指导临床监测策略。

相似文献

1
Risk and clinical implications of histological transformation in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: A population-based analysis.黏膜相关淋巴组织结外边缘区B细胞淋巴瘤组织学转化的风险及临床意义:一项基于人群的分析。
Sci Rep. 2025 Jul 1;15(1):20407. doi: 10.1038/s41598-025-07413-8.
2
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
3
An Epidemiological Study on Survival in Lymphoma of Mucosa-Associated Lymphoid Tissue: A Comparative Analysis by Primary Tumor Location.黏膜相关淋巴组织淋巴瘤生存情况的流行病学研究:按原发肿瘤部位的比较分析
J Invest Surg. 2025 Dec;38(1):2523858. doi: 10.1080/08941939.2025.2523858. Epub 2025 Jun 30.
4
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
5
Development of Nomogram for Predicting the Overall Survival of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Based on Clinical Data and Systemic Inflammation Markers.基于临床数据和全身炎症标志物的弥漫性大B细胞淋巴瘤(DLBCL)患者总生存预测列线图的开发
Asian Pac J Cancer Prev. 2025 Jun 1;26(6):2145-2154. doi: 10.31557/APJCP.2025.26.6.2145.
6
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
7
Predictors of survival in gastric mucosa-associated lymphoid tissue lymphoma: An updated surveillance, epidemiology, and end results-based analysis of age and gender disparities.胃黏膜相关淋巴组织淋巴瘤生存的预测因素:基于监测、流行病学及最终结果的年龄和性别差异的最新分析
World J Clin Oncol. 2025 Jun 24;16(6):106408. doi: 10.5306/wjco.v16.i6.106408.
8
Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients.黏膜相关淋巴组织结外边缘区B细胞淋巴瘤向弥漫性大B细胞淋巴瘤组织学转化的临床病理特征:467例患者分析
Br J Haematol. 2016 Sep;174(6):923-31. doi: 10.1111/bjh.14153. Epub 2016 Jul 27.
9
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
10
Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.利妥昔单抗(美罗华)治疗侵袭性非霍奇金淋巴瘤:系统评价与经济学评估
Health Technol Assess. 2004 Sep;8(37):iii, ix-xi, 1-82. doi: 10.3310/hta8370.

本文引用的文献

1
Epidemiologic characteristics of 22,086 patients discharged from the Department of Orthopaedic Trauma at a military hospital between 2013 and 2022: a retrospective real-world study.2013年至2022年期间某军队医院创伤骨科出院的22086例患者的流行病学特征:一项回顾性真实世界研究
Ann Med. 2025 Dec;57(1):2447404. doi: 10.1080/07853890.2024.2447404. Epub 2024 Dec 28.
2
Chidamide and venetoclax synergistically regulate the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.西达本胺和维奈克拉通过MYCN/DKK3在B细胞急性淋巴细胞白血病中协同调节Wnt/β-连环蛋白信号通路。
Ann Hematol. 2025 Jan;104(1):489-501. doi: 10.1007/s00277-024-06110-2. Epub 2024 Nov 28.
3
Clinicopathological characteristics and genomic profiling in patients with transformed lymphoma: a monocentric retrospective study.
转化型淋巴瘤患者的临床病理特征和基因组分析:一项单中心回顾性研究。
Ann Med. 2024 Dec;56(1):2419556. doi: 10.1080/07853890.2024.2419556. Epub 2024 Oct 26.
4
Transformation of marginal zone lymphoma to Hodgkin lymphoma.边缘区淋巴瘤转化为霍奇金淋巴瘤。
Blood Adv. 2024 Sep 10;8(17):4559-4562. doi: 10.1182/bloodadvances.2024013434.
5
Risk of transformation by frontline management in follicular and marginal zone lymphomas: a US population-based analysis.滤泡性和边缘区淋巴瘤一线治疗后转化风险:一项基于美国人群的分析。
Blood Adv. 2024 Aug 27;8(16):4423-4432. doi: 10.1182/bloodadvances.2024013499.
6
Transformation risk and associated survival outcome of marginal zone lymphoma: A nationwide study.边缘区淋巴瘤的转化风险及相关生存结局:一项全国性研究。
Ann Hematol. 2024 Oct;103(10):4211-4222. doi: 10.1007/s00277-024-05688-x. Epub 2024 Mar 9.
7
A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics.一项基于人群的转化边缘区淋巴瘤研究:确定与预后相关的特征。
Blood Cancer J. 2023 Sep 1;13(1):130. doi: 10.1038/s41408-023-00903-w.
8
Marginal zone lymphoma: 2023 update on diagnosis and management.边缘区淋巴瘤:2023年诊断与管理更新
Am J Hematol. 2023 Oct;98(10):1645-1657. doi: 10.1002/ajh.27058. Epub 2023 Aug 21.
9
Transformation and survival in marginal zone lymphoma: a Finnish nationwide population-based study.边缘区淋巴瘤的转化和生存:一项芬兰全国基于人群的研究。
Blood Cancer J. 2023 Apr 25;13(1):62. doi: 10.1038/s41408-023-00831-9.
10
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.《世界卫生组织造血与淋巴组织肿瘤分类》第五版:淋巴肿瘤。
Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.